Intensity Therapeutics (INTS) Competitors

$4.58 -0.05 (-1.08%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$4.55 -0.03 (-0.66%)

As of 07:02 AM Eastern

INTS vs. ESLA, OKUR, XLO, ZYBT, and ELUT

Should you buy Intensity Therapeutics stock or one of its competitors? MarketBeat compares Intensity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intensity Therapeutics include Estrella Immunopharma (ESLA), OnKure Therapeutics (OKUR), Xilio Therapeutics (XLO), Zhengye Biotechnology (ZYBT), and Elutia (ELUT). These companies are all part of the "med - biomed/gene" industry.

How does Intensity Therapeutics compare to Estrella Immunopharma?

Intensity Therapeutics (NASDAQ:INTS) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 718.78%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 614.29%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Intensity Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 7.1% of Intensity Therapeutics shares are held by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Intensity Therapeutics had 10 more articles in the media than Estrella Immunopharma. MarketBeat recorded 11 mentions for Intensity Therapeutics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.96 beat Intensity Therapeutics' score of 0.72 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Intensity Therapeutics	Positive
Estrella Immunopharma	Positive

Estrella Immunopharma's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Estrella Immunopharma	N/A	N/A	-430.91%

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.35	N/A

Summary

Intensity Therapeutics beats Estrella Immunopharma on 10 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Intensity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OnKure Therapeutics presently has a consensus target price of $27.00, indicating a potential upside of 776.62%. Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 718.78%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

OnKure Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market.

In the previous week, Intensity Therapeutics had 10 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Intensity Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Intensity Therapeutics' score of 0.72 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Intensity Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

OnKure Therapeutics' return on equity of -61.02% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Summary

OnKure Therapeutics beats Intensity Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to Xilio Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 718.78%. Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 243.56%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Intensity Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Intensity Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Xilio Therapeutics	$53.48M	0.91	-$35.04M	-$3.55	N/A

In the previous week, Intensity Therapeutics had 8 more articles in the media than Xilio Therapeutics. MarketBeat recorded 11 mentions for Intensity Therapeutics and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.98 beat Intensity Therapeutics' score of 0.72 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.1% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Intensity Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Intensity Therapeutics' return on equity of -136.82% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Intensity Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.16, indicating that its stock price is 116% less volatile than the broader market.

Summary

Intensity Therapeutics beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Intensity Therapeutics (NASDAQ:INTS) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Intensity Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Intensity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Zhengye Biotechnology	$16.64M	2.63	-$9.98M	N/A	N/A

3.7% of Intensity Therapeutics shares are owned by institutional investors. 7.1% of Intensity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Intensity Therapeutics had 11 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 11 mentions for Intensity Therapeutics and 0 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.44 beat Intensity Therapeutics' score of 0.72 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Intensity Therapeutics	Positive
Zhengye Biotechnology	Positive

Intensity Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 718.78%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Intensity Therapeutics beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to Elutia?

Elutia (NASDAQ:ELUT) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

74.0% of Elutia shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 7.1% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Elutia has a net margin of 312.09% compared to Intensity Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-58.27%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Elutia has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market.

Elutia has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.83	$53.38M	$0.86	1.28
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

In the previous week, Intensity Therapeutics had 2 more articles in the media than Elutia. MarketBeat recorded 11 mentions for Intensity Therapeutics and 9 mentions for Elutia. Intensity Therapeutics' average media sentiment score of 0.72 beat Elutia's score of -0.06 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Elutia currently has a consensus price target of $6.00, indicating a potential upside of 445.45%. Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 718.78%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Intensity Therapeutics is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Elutia beats Intensity Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.51M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-0.80	18.13	20.64	25.23
Price / Sales	N/A	289.87	554.85	79.36
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.93	6.57	9.66	6.63
Net Income	-$11.61M	$24.35M	$3.56B	$335.59M
7 Day Performance	-6.15%	-2.53%	-1.65%	-1.20%
1 Month Performance	-13.58%	-3.55%	-2.60%	-1.16%
1 Year Performance	-54.99%	53.51%	30.07%	28.10%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	3.5652 of 5 stars	$4.58 -1.1%	$37.50 +718.8%	-56.6%	$12.51M	N/A	N/A	2,021	News Coverage
ESLA Estrella Immunopharma	2.8695 of 5 stars	$1.20 -0.8%	$8.00 +566.7%	+16.8%	$51.20M	N/A	N/A	N/A	Earnings Report Short Interest Decrease Gap Up
OKUR OnKure Therapeutics	3.6012 of 5 stars	$3.40 +0.3%	$27.00 +694.1%	+54.0%	$46.48M	N/A	N/A	N/A
XLO Xilio Therapeutics	3.0547 of 5 stars	$7.76 +0.4%	$28.00 +260.8%	-32.3%	$46.43M	$43.77M	N/A	70	News Coverage Earnings Report Analyst Downgrade Gap Down
ZYBT Zhengye Biotechnology	1.2839 of 5 stars	$0.96 -5.0%	N/A	-88.2%	$45.46M	$116.36M	N/A	278	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. ESLA, OKUR, XLO, ZYBT, and ELUT

How does Intensity Therapeutics compare to Estrella Immunopharma?

Summary

How does Intensity Therapeutics compare to OnKure Therapeutics?

Summary

How does Intensity Therapeutics compare to Xilio Therapeutics?

Summary

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Summary

How does Intensity Therapeutics compare to Elutia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. ESLA, OKUR, XLO, ZYBT, and ELUT

How does Intensity Therapeutics compare to Estrella Immunopharma?

Do analysts recommend INTS or ESLA?

Which has more volatility and risk, INTS or ESLA?

Do insiders and institutionals hold more shares of INTS or ESLA?

Does the media favor INTS or ESLA?

Is INTS or ESLA more profitable?

Which has better earnings & valuation, INTS or ESLA?

Summary

How does Intensity Therapeutics compare to OnKure Therapeutics?

Do institutionals and insiders believe in OKUR or INTS?

Do analysts recommend OKUR or INTS?

Which has more volatility & risk, OKUR or INTS?

Does the media prefer OKUR or INTS?

Which has better valuation and earnings, OKUR or INTS?

Is OKUR or INTS more profitable?

Summary

How does Intensity Therapeutics compare to Xilio Therapeutics?

Do analysts rate INTS or XLO?

Which has preferable valuation & earnings, INTS or XLO?

Does the media favor INTS or XLO?

Do institutionals & insiders hold more shares of INTS or XLO?

Is INTS or XLO more profitable?

Which has more volatility & risk, INTS or XLO?

Summary

How does Intensity Therapeutics compare to Zhengye Biotechnology?

Which has more volatility & risk, INTS or ZYBT?

Which has stronger valuation & earnings, INTS or ZYBT?

Do insiders & institutionals believe in INTS or ZYBT?

Does the media favor INTS or ZYBT?

Do analysts recommend INTS or ZYBT?

Is INTS or ZYBT more profitable?

Summary

How does Intensity Therapeutics compare to Elutia?

Do insiders and institutionals hold more shares of ELUT or INTS?

Is ELUT or INTS more profitable?

Which has more risk and volatility, ELUT or INTS?

Which has preferable valuation & earnings, ELUT or INTS?

Does the media prefer ELUT or INTS?

Do analysts recommend ELUT or INTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools